NASDAQ:TEM

Tempus Ai Stock News

Buy TEM

*Your capital is at risk

$55.93

-2.30 (-3.95%)

At Close: Jul 13, 2026

Tempus AI: Building Ultimate Healthcare Data Dominance

03:27pm, Monday, 13'th Jul 2026

Tempus AI, Inc. earns a Strong Buy rating due to its transformation into a healthcare data giant with high-margin, rapidly growing data services. TEM's Q1 2026 data segment revenue surged 40% YoY to $

Squeeze Watch: 10 Stocks Bears Love to Hate Most Right Now

02:29pm, Monday, 13'th Jul 2026

Short‑interest screens are lighting up with a tight cluster of mid‑ and large‑cap names where bearish bets have gone all‑in, turning these stocks into live‑wire squeeze candidates rather tha

Tempus to Report Second Quarter 2026 Financial Results on July 30

09:00am, Thursday, 09'th Jul 2026

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the second

Tempus AI: Buy On Diagnostics Momentum And AI Platform Expansion

03:50am, Tuesday, 30'th Jun 2026

Tempus receives a Buy rating, leveraging a unique AI-driven diagnostics and data platform with expanding FDA-approved offerings. Recent FDA approval for xT CDx's tumor-only indication and the upcoming

Tempus Announces Research Collaboration with Angiosarcoma Awareness, Inc. to Uncover Insights on Rare Cancers

08:30am, Thursday, 25'th Jun 2026

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a research collaboration with A

Should You Retain Tempus AI Stock In Your Portfolio Now?

01:51pm, Thursday, 18'th Jun 2026

TEM's diagnostics growth and expanding data deals support momentum, but sizable GAAP losses and execution challenges could keep shares volatile.

Tempus AI (TEM) Price Forecast: Consolidation Bottom Breakout Looms

05:07pm, Tuesday, 16'th Jun 2026

Tempus AI (TEM) has consolidated near trend lows for four months, forming a double bottom with breakout resistance at $54.75 and a first target near $64.54.

Tempus AI: AI Precision Medicine With A Moat

11:32am, Thursday, 11'th Jun 2026

Tempus AI trades at multi-year lows despite proprietary data advantages and robust AI-driven precision medicine capabilities. The company leverages 500+ petabytes of unique multimodal healthcare data

Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm

08:30am, Thursday, 11'th Jun 2026

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced publication of successful multi-site validation

Tempus AI: The Compression Has Outrun The Business - Upgrading To Buy

07:38am, Tuesday, 09'th Jun 2026

Tempus AI (TEM) now offers an attractive risk-reward setup, with valuations normalized to ~5.7x forward revenue and improved visibility on durable, high-margin revenues. Organic growth remains robust

Tempus AI: A Unique AI Business Model With Asymmetric Upside

06:36am, Tuesday, 09'th Jun 2026

Tempus AI is rated Strong Buy, leveraging a unique data moat and network effect in healthcare AI. TEM's Diagnostics and Data & Applications segments drive robust 36% YoY revenue growth, with expanding

Genetics in Medicine Open Study Demonstrates How Ambry Genetics' ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome Testing

06:00am, Tuesday, 09'th Jun 2026

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical genomic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced peer-reviewed research demonstrati

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by